IndieBio SF (http://sf.indiebio.co) is hosting conversations on the cutting edge of a new generation of biotech. We want to look at papers, play with data and meet the minds and hands that will accelerate biology.
The past few months have re-ignited the promise of DNA editing in the public mind.
• CRISPR/Cas Genome Editing (http://www.nytimes.com/2015/11/15/magazine/the-crispr-quandary.html)enjoyed the press usually reserved only by celebrities and highly expressive animals (http://www.grumpycats.com/).
• A one year old girl in UK had her T-cells reprogrammed to cure a rare leukemia (http://time.com/4103289/baby-in-remission-from-cancer-after-gene-editing-therapy/) after all other options had failed.
• Just as the year ended, a team in UT SouthWestern Med Center successfully edited a gene in mice to treat a Duchenne Muscular Dystrophy Model using CRISPR/Cas (http://medicalxpress.com/news/2015-12-gene-editing-technique-successfully-duchenne-muscular.html), a major milestone in the 30 years of research where no treatment has ever been found for DMD.
2016 Promises to be an even bigger year as thousands of known diseases and many newly discovered congenital diseases begin to fall to new technologies.
Tonights discussion will be headed by several entrepreneurs in this exciting new space. Beyond manipulating DNA, the very logic of cells, tissues and engineering new health capabilities will begin to emerge. s
The general public as well as biotechnology professionals are invited to come for a deep dive of these events and on what might come next.